FDA’s Avian Flu Rapid Response Team Will Make Antiviral Reviews A Priority
This article was originally published in The Pink Sheet Daily
Executive Summary
The newly created team will look at vaccine development, but its main focus will be addressing roadblocks to manufacturing treatments such as Roche’s Tamiflu.
You may also be interested in...
FDA Assembles Pandemic Flu Task Force
Members of the Task Force on Pandemic Influenza will be culled from 14 agency offices.
FDA Assembles Pandemic Flu Task Force
Members of the Task Force on Pandemic Influenza will be culled from 14 agency offices.
Roche To Meet With Generic Firms On Tamiflu Rights After Intervention From Senators
Roche agrees to meet with Teva, Mylan, Ranbaxy and Barr to discuss granting manufacturing rights for Tamiflu in order to meet growing global demand for the avian flu antiviral.